Infinity Pharmaceuticals adds Dr Richard Gaynor to its Board of Directors

– USA, MA –  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), announced today the appointment of Richard Gaynor, M.D. to its Board of Directors, effective March 16, 2020.

“We are thrilled to have Dr. Gaynor join the board as we advance IPI-549 to important data readouts,” said Adelene Perkins, CEO and Chair.

“Richard’s tremendous expertise, first as a practicing academic oncologist and then as a seasoned pharma executive at Lilly and Neon Therapeutics, is particularly well suited to help guide the advancement of our IPI-549 clinical programs across a wide range of indications and treatment regimens. We look forward to Dr. Gaynor’s engagement as we approach a number of important clinical data milestones,” she added.

About Dr Richard Gaynor

Richard Gaynor, M.D. is currently the President of Research and Development for Neon Therapeutics (Nasdaq: NTGN), a biotechnology company developing novel neoantigen-targeted T cell therapies. Prior to his tenure at Neon Therapeutics, Dr. Gaynor spent 15 years in a series of senior roles at Lilly Oncology, most recently as Senior Vice President Clinical Development and Medical Affairs, where he chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE. Prior to that role, Dr. Gaynor also led preclinical and early clinical oncology research at Eli Lilly. Dr. Gaynor began his career in academia, spending nine years on the faculty at UCLA School of Medicine, followed by 11 years on the faculty at the University of Texas Southwestern Medical School, including time serving as the chief of hematology-oncology and director of the Simmons Cancer Center.

“I am excited to join the board of directors at Infinity to help advance IPI-549 as the first selective PI3K-gamma inhibitor targeting immune-suppressive myeloid cells”, said Dr. Gaynor. “There is increasing evidence that blocking this pathway may play a crucial role in improving outcomes in patients who are unresponsive or refractory to current immunotherapy treatments. Infinity’s current trials are well-positioned to demonstrate the importance of targeting the immune-suppressive myeloid compartment in overcoming the limitations of immune therapies and improving outcomes for patients.”

He holds an M.D. from the University of Texas Southwestern Medical School and, following his residency in internal medicine there, he completed fellowship training in hematology-oncology at the UCLA School of Medicine. He is the author of nearly 150 publications and participates on numerous advisory boards and committees, including the American Association of Cancer Research, the Stand Up To Cancer scientific advisory committee, and the Damon Runyon Cancer Research Foundation. Dr. Gaynor also serves on the board of directors of Alkermes plc.

About Infinity and IPI-549

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of IPI-549 combined with Opdivo in I/O naïve urothelial cancer. MARIO-3 is the first IPI-549 combination study in front-line advanced cancer patients and is evaluating IPI-549 in combination with Tecentriq and Abraxane in front-line TNBC and in combination with Tecentriq and Avastin in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of IPI-549 plus AB928 plus Doxil in advanced TNBC patients. In 2019 Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies, Infinity is evaluating IPI-549 in the anti-PD-1 refractory, I/O-naïve, and front-line settings.

For more information: http://www.infi.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.